title: Déjà vu for breast cancer two?
authors.forename: Vered
authors.initials: V
authors.lastname: Stearns
authors.forename: Nancy E
authors.initials: NE
authors.lastname: Davidson
mesh_terms: D000367:Age Factors; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000032:analysis*; D001943:Breast Neoplasms / Q000737:chemistry* / Q000188:drug therapy / Q000473:pathology; D002986:Clinical Trials as Topic; D018572:Disease-Free Survival; D020847:Estrogen Receptor Modulators / Q000627:therapeutic use; D005260:Female; D006801:Humans; D015994:Incidence; D008875:Middle Aged; D009376:Neoplasms, Hormone-Dependent / Q000737:chemistry* / Q000188:drug therapy / Q000473:pathology; D009378:Neoplasms, Multiple Primary / Q000737:chemistry* / Q000517:prevention & control; D016609:Neoplasms, Second Primary / Q000737:chemistry* / Q000517:prevention & control; D011237:Predictive Value of Tests; D011960:Receptors, Estrogen / Q000032:analysis*; D011980:Receptors, Progesterone / Q000032:analysis*; D012189:Retrospective Studies; D016019:Survival Analysis; D013629:Tamoxifen / Q000627:therapeutic use
chemical_list: D018931:Antineoplastic Agents, Hormonal; D014408:Biomarkers, Tumor; D020847:Estrogen Receptor Modulators; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D013629:Tamoxifen